Prevalence of mental health problems among people living with HIV

Fiona Lampe

Institute for Global Health, University College London

Antiretrovirals, Sexual Transmission Risk and Attitudes

Outline

- Measuring mental health problems

- Prevalence among people with HIV in Europe

- Comparison to HIV-negative people

- Comparison to people with other long-term health conditions

- Variation by socio-demographics and time with HIV

Outline

- **Measuring mental health problems**

- Prevalence among people with HIV in Europe

- Comparison to HIV-negative people

- Comparison to people with other long-term health conditions

- Variation by socio-demographic factors and time with HIV

Mental health disorders

Measuring depression prevalence

Current depression

Self-report of depression e.g. Euroqol

Clinical interview for depression

Depression symptom questionnaire e.g. PHQ-9 HADS CES-D BDI

Currently receiving treatment for depression

Measuring depression prevalence

Current depression

Self-report of depression e.g. Euroqol

Clinical interview for depression

Depression symptom questionnaire e.g. PHQ-9 HADS CES-D BDI

Currently receiving treatment for depression

Previous depression: symptoms, diagnosis or treatment

Outline

- Measuring mental health problems

- **Prevalence among people with HIV in Europe**

- Comparison to HIV-negative people

- Comparison to people with other long-term health conditions

- Variation by socio-demographic factors and time with HIV

Research on mental health among HIV-positive people in Europe

- Observational studies measuring mental health variables in HIV-positive people in **Europe in 2008-2018**

- Studies from at least 20 European countries (depression; quality of life; anxiety; other)

Albania: *Morrison, J Infect Dev Ctries 2014, Croat Med J 2011*

Belgium: *Degroote, Acta Clin Belgica 2014*

Denmark: *Rodkjaer, Int J Infect Dis 2014, HIV Med 2016; Slot, HIV Med 2015,*

Estonia: *Lemsalu, AIDS Beh 2017*

Finland: *Nobre, AIDS Care 2016*

France: *Figuero, HIV Med 2010; Cuzin, HIV Med 2016; Feuillet, HIV Med 2017; Carrieri, PLoS ONE 2017, Enel AIDS Care 2018*

Germany: *Ronel, Psychol Hlth Med 2018*

Italy: *Marando, AIDS Care 2016; Venturini, AIDS Care 2017*

Netherlands: *Sumari-de Boer, AIDS Beh 2012; Oberje, AIDS Beh 2015; Langebeek, AIDS 2017; Verbooy AIDS Care 2018; Engelhard, AIDS 2018*

Norway: *Eller, AIDS Care 2010*

Poland: *Nobre, AIDS Care 2016; Rzeszutek, Arch Wom Hlth 2018*

Portugal: *Braganca, AIDS Beh 2011; Nobre, AIDS Care 2016; Monteiro, AIDS Care 2016; Maia, J Assoc Nur AIDS Care 2017; Serrao Int J Infect Dis 2019*

Romania: *Rsolul, AIDS Care 2018; Ursoiu, AIDS Care 2018*

Russia: *Lasser, PLoS ONE 2018*

Spain: *Briongos Figuero, HIV Med 2011; Bayon, Antiv Th 2012; Gutierrez, HIV Med 2014; Baller-Arnai, AIDS Beh 2016; Bayon-Perez, AIDS Care 2016; Fumaz, Eu J Psy 2019*

Sweden: *Zeluf-Andersson, AIDS Care 2019*

**Switzerland:** *Anagnostopoulos, PLoS ONE 2015*

Turkey: *Demirel, AIDS Care 2019*

UK & Ireland: *Miners, Lancet HIV 2014; O'Brien, Hlth Qual Out 2015; Underwood, HIV Med 2016; McGowan, HIV Med 2017; Sherr, J Vir Erad 2016; Patel, Int J STD AIDS 2016; Murphy, AIDS Care 2018; Tariq, PRIME-report 2018; De Francesco, HIV Med 2019*

**Europe:** *Robertson, AIDS Care 2014; Tirado-Munoz, Arch Wom Hlth 2018*

Measuring depression prevalence

Current depression

Self-report of depression e.g. Euroqol

Clinical interview for depression

Currently receiving treatment for depression

Depression symptom questionnaire e.g. PHQ-9 HADS CES-D BDI

Previous depression: symptoms, diagnosis or treatment

Depression - symptom questionnaire, HIV-positive, Europe

Denmark 2008 N=304
Denmark 2013 N=501
Belgium 2012 N=218
Spain 2007-8 N=150

BDI-II ≥ 20

UK & IRE *(POPPY)* Age ≥ 50, 2013-14 N=975
England *(ASTRA)* 2011-12 N=3258
England Women, 2014 N=140
Netherlands *(AGEhIV)* 2010-12 N=541
England *(PRIME)* Women Age 45-60 2015 N=869

PHQ-9 ≥ 10

PHQ-2 ≥ 3

UK & IRE 2014 N=278
Germany (*'50/2010'*) Age ≥ 50, 2008-9 N=183
W Europe *(CRANIum)* 2010-11 N=2863

HADS ≥ 8

UK & IRE *(POPPY)* Age ≥ 50, 2013-14 N=952
Netherlands On ART, 2008-9 N=201
Italy *(DHIVA)* <2015 N=690
Spain On ART, 2008 N=799
Russia 2008-9 N=492

CES-D-20 ≥ 16

France (*VESPA2*) 2011 (past year) N=2392
France (*VISAGE*) Age ≥ 50, 2013-14 N=494
Portugal 2008 N=130
Estonia 2013 N=729

CIDI-SF
Mini GDS
HAM-D ≥ 10
EST-Q2 ≥ 12

Prevalence (%)
and 95% CI

0 10 20 30 40 50 60 70 80

Depression - symptom questionnaire, HIV-positive, Europe

Denmark 2008 N=304
Denmark 2013 N=501
Belgium 2012 N=218
Spain 2007-8 N=150

BDI-II ≥ 20

UK & IRE *(POPPY)* Age ≥ 50, 2013-14 N=975
England *(ASTRA)* 2011-12 N=3258
England Women, 2014 N=140
Netherlands *(AGEhIV)* 2010-12 N=541
England *(PRIME)* Women Age 45-60 2015 N=869

PHQ-9 ≥ 10

PHQ-2 ≥ 3

UK & IRE 2014 N=278
Germany (*'50/2010'*) Age ≥ 50, 2008-9 N=183
W Europe (*CRANIum*) 2010-11 N=2863

HADS ≥ 8

UK & IRE *(POPPY)* Age ≥ 50, 2013-14 N=952
Netherlands On ART, 2008-9 N=201
Italy *(DHIVA)* <2015 N=690
Spain On ART, 2008 N=799
Russia 2008-9 N=492

CES-D-20 ≥ 16

General population prevalence for PHQ-9, PHQ-2, HADS Range: 5-12%

France (*VESPA2*) 2011 (past year) N=2392
France (*VISAGE*) Age ≥ 50, 2013-14 N=494
Portugal 2008 N=130
Estonia 2013 N=729

CIDI-SF
Mini GDS
HAM-D ≥ 10
EST-Q2 ≥ 12

Prevalence (%) and 95% CI

0   10   20   30   40   50   60   70   80

Anxiety - symptom questionnaire, HIV-positive, Europe

England *(ASTRA)* 2011-12 N=3258
England Women, 2014 N=140
England *(PRIME)* Women Age 45-60 2015 N=869

GAD-7 ≥ 10

GAD-2 ≥ 3

UK & IRE 2014 N=278
Germany (*'50/2010'*) Age ≥ 50, 2008-9 N=183
W Europe (*CRANIum*) 2010-11 N=2863

HADS ≥ 8

**Prevalence (%)
and 95% CI**

0   10   20   30   40   50   60   70   80

Measuring depression prevalence

Current depression

Self-report of depression e.g. Euroqol

Clinical interview for depression

Currently receiving treatment for depression

Depression symptom questionnaire e.g. PHQ-9 HADS CES-D BDI

Previous depression: symptoms, diagnosis or treatment

Depression / anxiety – self-report, HIV-positive, Europe

EQ-5D-3L Self-report of 'moderate' or 'severe' anxiety or depression

England *(ASTRA)* 2011-12 N=3151
Italy *(IANUA),* 2015 N=943

England general population *(HSE)**, 2011 N=7424

*Miners et la, Lancet HIV 2014

Prevalence (%) and 95% CI

0   10   20   30   40   50   60   70   80

Measuring depression prevalence

Current depression

Self-report of depression e.g. Euroqol

Clinical interview for depression

Depression symptom questionnaire e.g. PHQ-9 HADS CES-D BDI

Currently receiving treatment for depression

Previous depression: symptoms, diagnosis or treatment

Depression - clinical interview, HIV-positive, Europe

N=113 HIV-positive people on ART,
no prior mental health diagnosis
Spain 2014

N=709 HIV-positive people
DHIVA Study, Italy <2015

- Semi-structured interview by psychiatrist or psychologist

- Prevalence of undiagnosed depression: **21.2% (13.3%, 29.2%)**

**Prevalence of depressive symptoms**

Legend: ■ Mild ■ Moderate ■ Severe

Categories: Physician assessment, CES-D-20 score

X-axis: Prevalence (%) — 0 10 20 30 40 50 60 70 80 90 100

Bayon-Perez et al. AIDS Care 2016

Adapted from Marando et al. AIDS Care 2016

Measuring depression prevalence

Current depression

Clinical interview for depression

Self-report of depression e.g. Euroqol

Depression symptom questionnaire e.g. PHQ-9 HADS CES-D BDI

Currently receiving treatment for depression

Previous depression: symptoms, diagnosis or treatment

Depression – receiving treatment, HIV-positive, England

N=3258 HIV-positive people
ASTRA Study, England 2011-2012

Treatment=medicine or other therapy for depression

PHQ-9 symptoms defined by PHQ-9 major or other depressive disorder (PHQ-9 DD)

Treatment only: 8.5 % (N=277)

Treatment and PHQ-9 symptoms: 10.9% (N=355)

Prevalence (%) — y-axis: 0, 10, 20, 30, 40, 50

Prevalence of treated depression: 19.4%
TOTAL with evidence of depression: 35.2% (N=1148)
of whom 516 (45.0%) were not receiving treatment

Measuring depression prevalence

Current depression

Clinical interview for depression

Self-report of depression e.g. Euroqol

Depression symptom questionnaire e.g. PHQ-9 HADS CES-D BDI

Currently receiving treatment for depression

Previous depression: symptoms, diagnosis or treatment

Mental health – previous diagnosis, HIV-positive, Europe

N=4424 HIV-positive
Positive Voices Study, UK 2017

Prevalence of ever diagnosed conditions

Bar chart showing prevalence (%) of ever diagnosed conditions:
- Depression: ~33%
- Anxiety: ~26%
- Insomnia/Sleep disorder: ~15%
- PTSD: ~5%
- Eating disorder: ~3%
- Personality disorder: ~2%
- Psychosis/Schizophrenia: ~2%
- Bipolar disorder: ~2%

(x-axis: 0, 10, 20, 30, 40, 50 (%))

Acknowledgements, Meaghan Kall, Public Health England

N=401 HIV-positive
Portugal 2019

Percentage with diagnosis depression/chronic anxiety documented in medical records: 24%

Serrao et al. Int J Infect Dis 2019

N=2189 HIV-positive
GPRD cohort study, UK 2005

Percentage with primary care recorded symptoms or diagnosis of mental health problem *following* HIV diagnosis:

- 37.3% of men
- 27.0% of women

Evans et al. Sex Trans Infect 2009

N=79 HIV-positive
Albania 2009

Percentage with history of mental health diagnosis *following* HIV diagnosis:

- 62% had depression diagnosis
- 82% had anxiety diagnosis

Morrison et al. Croat Med J 2011

# Psychotropic drug use: HIV-positive vs general population, Denmark

N=4460 HIV-positive
*N=40140 age-sex-matched general population comparison cohort*
Danish HIV Cohort Study & Danish National Prescription Registry, 1995-2009

Anti-depressants

Utilisation rate: defined daily doses per 1000 person-days

HIV-positive

General population

Years after HIV diagnosis

Hypnotics and sedatives

HIV-positive

General population

Years after HIV diagnosis

Adapted from Rasmussen et al. HIV Medicine 2014

Outline

- Measuring mental health problems

- Prevalence among people with HIV in Europe

- **Comparison to HIV-negative people**

- Comparison to people with other long-term health conditions

- Variation by socio-demographic factors and time with HIV

Mental health: HIV-positive vs HIV-negative, UK & Ireland

HIV-negative people frequency matched to HIV-positive people for: gender, sexual orientation; ethnicity; location

# Mental health: HIV-positive vs HIV-negative, Netherlands

N=541 HIV-positive
N=524 HIV-negative
AGEhIV Cohort Study, Netherlands 2010-2012, *age ≥45 years*

HIV-negative

HIV-positive

P<0.01
Odds Ratio (OR): 1.9
Adjusted OR: 2.1

0 10 20 30 40 50 60 70 80 90 100

Prevalence of depressive symptoms, PHQ-9 score ≥ 10

Adjusted estimates adjusted for age, demographic factors, number of comorbidities

HIV-negative

HIV-positive

P<0.05
Effect size: 0.12
Adjusted effect size: 0.16

40 42 44 46 48 50 52 54 56 58 60

Mental Health Summary (MHS) Score* (95% CI) from SF-36

*Higher values denote better quality of life

Adapted from Langebeek et al. AIDS 2017

Mental heath: HIV-positive vs HIV-negative, England

N=2865 HIV-positive
N=2865 HIV-negative / undiagnosed
ASTRA and AURAH studies, England 2011-12 and 2013-14, *age ≤70 years, matched analysis**

P<0.001 for comparisons for all factors, logistic regression with robust SEs

*HIV-negative people matched to HIV-positive people (with replacement) for: gender/sexual orientation; age; ethnicity; education level.

Lampe et al. AIDS conference 2018

Mental heath: HIV-positive vs HIV-negative. Engl...

N=2865 HIV-positi...

N=2865 HIV...

ASTRA and AURAH stu...

Included studies from 1988 to 1998
Frequency of major depression 2-fold higher fro HIV+ve vs HIV-ve

Article

Meta-Analysis of the Relationship Between HIV Infection and Risk for Depressive Disorders

Jeffrey A. Ciesla, M.A.

John E. Roberts, Ph.D.

Objective: Each of 10 published studies investigating the relationship between HIV infection and risk for depressive disorders concluded that HIV-positive individuals are at no greater risk for depression than comparable HIV-negative individuals. This study used meta-analytic techniques to further examine the relationship between depressive disorders and HIV infection.

Method: Meta-analytic techniques were used to aggregate and reanalyze the data from 10 studies that compared HIV-positive and HIV-negative individuals for rates of major depressive disorder (N=2,596) or dysthymic disorder (N=1,822).

Results: The frequency of major depressive disorder was nearly two times higher in HIV-positive subjects than in HIV-negative comparison subjects. On the other hand, findings were inconclusive with regard to dysthymic disorder. Rates of depression do not appear to be related to the sexual orientation or disease stage of infected individuals.

Conclusions: Although the majority of HIV-positive individuals appear to be psychologically resilient, this meta-analysis provides strong evidence that HIV infection is associated with a greater risk for major depressive disorder. Future research should focus on identifying pathways of risk and resilience for depression within this population.

*HIV-negative people matched ...
(with replacement) for: gender/...
age; ethnicity; education level.

Lampe et al. AIDS conference 2018

Outline

- Measuring mental health problems

- Prevalence among people with HIV in Europe

- Comparison to HIV-negative people

- **Comparison to people with other long-term health conditions**

- Variation by socio-demographic factors and time with HIV

Quality of life – HIV-positive vs other conditions, Germany

N=255 HIV-positive
N=249 with diabetes type 2
N=257 with minor health conditions
Cohort Study '50/2010', 2008-2009, participants aged ≥ 50

Study population	N	Quality of life (SF-36) Mental health mean score*		Prevalence (%) using HADS (score ≥ 8)			
				Depression		Anxiety	
		BL	12M	BL	12M	BL	12M
HIV	255	45.5	45.8	26.2	27.9	34.4	35.0
DM type 2	249	50.0	49.5	22.2	26.1	26.8	32.4
Minor health conditions	257	49.2	48.8	17.6	17.1	30.5	31.4
		p=0.009, adjusted for age		*p=0.12*	*p=0.024*	*p=0.25*	*p=0.75*

*Higher values denote better quality of life

Quality of life – HIV-positive vs other conditions, Netherlands

N=311 HIV-positive (from ATHENA, 2013-14)
N=119 with diabetes type 1 (Cohort study, 2010)
N=2114 with diabetes type 2 (RCT population, 2009-2010)
N=250 with rheumatoid arthritis (RCT population, 2007-2011)

Study population	N	Quality of life (SF-36) mean score*		Adjusted~ odds ratio (95% CI) for poor health score#	
		Physical health	Mental health	Poor physical health	Poor mental health
HIV	331	53.5	50.7	1	1
DM type 1	119	52.3	54.9	0.8 (0.4, 1.3)	0.3 (0.2, 0.6)
DM type 2	2114	50.0	56.4	0.9 (0.7, 1.3)	0.3 (0.2, 0.4)
Rheumatoid arthritis	250	42.0	57.7	3.1 (2.2, 4.5)	0.3 (0.2, 0.5)
				p<0.001	*p<0.001*

*Higher values denote better quality of life

~Adjusted for age, gender, region of origin (Netherlands/other)

#Poor health = score in first quintile

Engelhard et al. AIDS 2018

Stigma and mental health, meta-analysis (global)

24 (& 6) studies of HIV-positive people 1996-2013

Correlation between stigma and depressive symptoms

-1   -0.5   0   0.5   1

Lower depression ←   → Higher depression

Correlation between stigma and anxiety symptoms

-1   -0.5   0   0.5   1

Lower anxiety ←   → Higher anxiety

Pooled association was similar for depression, attenuated for anxiety, in the few studies using multivariable analysis

Rueda et al. BMJ Open 2016

Outline

- Measuring mental health problems

- Prevalence among people with HIV in Europe

- Comparison to HIV-negative people

- Comparison to people with other long-term health conditions

- **Variation by socio-demographics factors and time with HIV**

# Gender, HIV-transmission-risk group, and depression, Europe

Depressive symptom episode in past 12 months (CIDI-SF)

Incidence and cumulative prevalence of depression diagnosis

SSA=sub-Saharan African

- Psychiatric disorder (lifetime prevalence) by DDSI: 87.2%

Feuillet et al. HIV Med 2017; Tirado-Munoz et al. Arch Wom Men Hlth 2018; Anagnostopoulos et al. PLOS One, 2015

Socio-economic factors and mental health, HIV-positive, Europe

N=3258 HIV-positive people
ASTRA Study, England 2011-2012

N=2973 HIV-positive people
Vespa2 Study, France 2011-2012

Qualifications: University degree (1317)
'A' / 'O' levels or equivalent (1348)
Other/missing (222)
None (371)

Money for basic needs: Yes (1392)
Mostly (836)
Sometimes (565)
No (400)

Housing: Homeowner (1083)
Renting, private (786)
Renting, council / HA (971)
Temporary / homeless (94)
Other/missing (324)

Prevalence PHQ-9 depressive symptoms(%)

Housing occupancy status	Prevalence ratio suicide risk~	
	Unadjusted	Adjusted*
Owner/tenant	1	1
Free accommodation	1.7	2.0
Tenant residential care	3.6	2.8
Homeless	4.0	4.9
	p<0.05	p<0.05

*From a model including gender/sexual orientation, nationality, HCV, living alone, CD4, psychosocial characteristics

~Having thought about and planned to commit suicide or attempted suicide during past year (6.3%)

Carrieri et al PLoS ONE 2017

Age and mental health, HIV-positive, Europe

N=2392 *Vespa2 Study, FRANCE 2011*

Age group (years)	N	Prevalence ratio for depressive symptoms past 12m (CIDI-SF)
25-34	281	2.0
35-44	637	1.5
45-54	783	1.5
55-65	459	1
		$p<0.001$

N=4422 *Swiss HIV Cohort Study, 2010-2013*

Age group (years)	P-Y	Incidence rate ratio for new depression diagnosis
<45	3818	1.6
45-54	3632	1.4
≥55	1898	1
		$p=0.005$

N=4119 *START RCT participants, 2009-2013*

Age group (years)	N	Quality of life (SF-12V2) mean score*	
		Physical health	Mental health
<30	1212	54.4	46.5
30-39	1403	54.3	48.4
40-49	1039	53.1	48.7
≥50	465	50.8	50.2
		$p<0.001$	$p<0.001$

*Higher values denote better quality of life

Anagnostopoulos et al. PLOS One, 2015; Feuillet et al. HIV Medicine 2016; Lifson et al. HIV Medicine 2015

Age, time since HIV diagnosis and depression, England

N=3258 HIV-positive people
ASTRA Study, England 2011-2012

Adjusted odds ratios (PR) of PHQ-9 ≥ 10, from logistic regression model including age group; years with diagnosed HIV; gender/sexual orientation; ethnicity

*Adapted from McGowan et al. HIV Medicine, 2017*

Depression: HIV-positive vs HIV-negative, England

N=2865 HIV-positive
N=2865 HIV-negative / undiagnosed
ASTRA and AURAH studies, England 2011-12 and 2013-14, *age ≤70 years, matched analysis**

Depression: PHQ-9 ≥10 or treatment for depression

AURAH: HIV-negative (N=2865)

ASTRA: HIV-positive. Time since diagnosis
<2 years (N=336)
2-5 years (N=447)
5-10 years (N=758)
10-15 years (N=577)
15-20 years (N=435)
≥ 20 years (N=298)

Adjusted OR (95% CI) of depression overall

*AURAH data matched to ASTRA data (with replacement) for: gender/sexual orientation; age; ethnicity; education level. Adjusted for all above factors using logistic regression with robust SEs.

Lampe et al. AIDS conference 2018

Factors linked to depressive symptoms among people with HIV

Demographic:
Younger age
Female gender
Non-white ethnicity (some studies)
IDU risk group

Socioeconomic:
Lower education
Unstable housing
Unemployment
Lower income
Poverty

Health/biological:
Pain and other physical symptoms
Cognitive impairment
HCV co-infection
Other co-morbidities
Longer time since HIV diagnosis (some studies)

Psychosocial:
No stable partner
Living alone
Low levels of supportive network
Stigma
High levels of HIV status disclosure
(some studies)

Lifestyle:
Smoking (some studies)
Alcohol problem (some studies)
Recreational drug use (some studies)
Sexual activity (no sex & condomless sex vs condom-protected, some studies)

Factors linked to depressive symptoms among people with HIV

Demographic:
Younger age
Female gender
Non-white ethnicity (some studies)
IDU risk group

Socioeconomic:
Lower education
Unstable housing
Unemployment
Lower income
Poverty

Health/biological:
Pain and other physical symptoms
Cognitive impairment
HCV co-infection
Other co-morbidities
Longer time since HIV diagnosis (some studies)

Psychosocial:
No stable partner
Living alone
Low levels of supportive network
Stigma
High levels of HIV status disclosure
(some studies)

Lifestyle:
Smoking (some studies)
Alcohol problem (some studies)
Recreational drug use (some studies)
Sexual activity (no sex & condomless sex vs condom-protected, some studies)

HIV OUTCOMES (cART era):
ART non-adherence
Viral load non-suppression

Depression and ART non-adherence, meta-analysis (global)

Study or Subgroup	Std. Mean Difference	SE	Std. Mean Difference IV, Random, 95% CI
1.1.1 medium to large effects			
Adherence self efficacy	0.603	0.0656	
1.1.2 small to medium effects			
Current substance use	-0.395	0.047	
Concerns about cART	-0.388	0.072	
Trust HIV care provider	0.377	0.043	
Belief necessity /utility	0.357	0.065	
Depressive symptoms	-0.305	0.024	
HIV stigma	-0.282	0.038	
Social support	0.237	0.029	
1.1.3 small effects			
PI in regimen	-0.196	0.038	
Daily dosing frequency	-0.193	0.029	
Financial constraints	-0.187	0.025	
1.1.4 < small effects			
Pill burden	-0.124	0.028	
Age	0.118	0.015	
Time since HIV diagnosis	-0.116	0.029	
CD4 cell count	-0.015	0.032	
Male gender	0.081	0.023	
Duration of cART	0.003	0.025	

-1   -0.5   0   0.5   1
lower adherence   higher adherence

Langebeek, BMC Medicine, 2014

Conclusions

- High prevalence of depression and anxiety among HIV-positive people in Europe in recent period, across countries and methods of assessment

- HIV-positive people substantially more likely to be experiencing mental health problems than comparable HIV-negative people - the difference is greatest for those diagnosed with HIV for longest

- Evidence that mental health may be poorer among people living with HIV than those living with other long-term physical health conditions

- Continued emphasis on detection and management of mental health conditions among those living with HIV is crucial, with links to appropriate support

- Highlights need for standardised collection of data on psychological symptoms and diagnoses for research studies and clinical care

Acknowledgments

Thanks to all who participated in the research studies